At the Annual European Congress of Rheumatology conference in Madrid this week, Aurinia Pharmaceuticals (NASDAQ: AUPH) presented new duration-of-remission data from a mid-stage study that’s good enough to suggest it could eventually change how doctors treat kidney failure in lupus patients.
Aurinia Pharmaceuticals is a clinical-stage biotechnology company, and its lead product candidate is voclosporin, a drug designed for use alongside CellCept in patients diagnosed with lupus nephritis (LN).
IMAGE SOURCE: GETTY IMAGES.